Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Paragon Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners, indicating no overlap in personnel for the current pending workload. The prosecution is also divided across distinct art units, reflecting a distributed start to their patent activities.
Examiner DUFFY, BRADLEY is the busiest examiner for the company, though he is only handling 1 pending office action. With only a few pending office actions total, the portfolio remains small and manageable across its distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19393395 | LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE | DUFFY, BRADLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19393395 | LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE | DUFFY, BRADLEY | — |
| 19297947 | FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19393395 | LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE | DUFFY, BRADLEY | 1643 | §101§103DP | Non-Final OA | — | Pending | Nov 18, 2025 |
| 19297947 | FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §103Other | Final Rejection | — | Pending | Aug 12, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialParagon Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bradley Duffy has the most, with 1 of Paragon Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
